CVS Health Corp (CVS)
Official siteHEALTHCARE • HEALTHCARE PLANS • NYSE
Market Cap: $113.35B
Last updated: Nov 17, 2026 at 4:40 PM ET
CVS Health Corp (CVS) Statistics
CVS Health (CVS) has a market cap of $113.35B and an enterprise value of $174.99B. Its net debt of $61.64B equals 54.38% of its market cap.
Total Valuation
Enterprise value is 54.38% above the market cap, as debt exceeds cash.
| Market Cap | $113.35B |
|---|---|
| Enterprise Value | $174.99B |
| Latest price (Nov 17, 2026) | $85.80 |
Key Dates
The next earnings report is expected on Feb 8, 2027, covering the quarter ending Dec 31, 2026. The last ex-dividend date was Oct 22, 2026.
| Next Earnings Date | Feb 8, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Last Ex-Dividend Date | Oct 22, 2026 |
| Last Payment Date | Nov 2, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 0.3x and 1.4x. Its year-end P/E ranged from 8.3x to 13.5x from 2016 to 2025.
| P/E Ratio | 10.3x |
|---|---|
| Forward P/E | 10.4x |
| P/S Ratio | 0.3x |
| Forward P/S | 0.3x |
| P/B Ratio | 1.4x |
| P/FCF Ratio | 7.1x |
| P/OCF Ratio | 6.1x |
| PEG Ratio | 0.8 |
Enterprise Valuation
Counting debt and cash, the company is valued at 8.7x EBITDA and 11.0x free cash flow.
| EV / Earnings | 15.8x |
|---|---|
| EV / Sales | 0.4x |
| EV / EBITDA | 8.7x |
| EV / EBIT | 11.5x |
| EV / FCF | 11.0x |
Price Statistics
The stock is up 11.16% over 52 weeks and trades 3.49% below its 50-day average.
| Beta (1Y) | 0.00 |
|---|---|
| 52-Week Change | +11.16% |
| 1-Month Change | -6.77% |
| 3-Month Change | -7.74% |
| 6-Month Change | -8.33% |
| 5-Year Change | +1.09% |
| 10-Year Change | +7.31% |
| Total Return (1Y) | +14.60% |
| Total Return (3Y CAGR) | +10.64% |
| Total Return (5Y CAGR) | +0.63% |
| Return vs SPY (1Y) | -0.59% |
| Max Drawdown (1Y) | -26.74% |
| Max Drawdown (3Y) | -43.97% |
| Sharpe Ratio (1Y) | 0.30 |
| Correlation with SPY (1Y) | 0.00 |
| 50-Day Average | $88.90 |
| 200-Day Average | $88.52 |
| 52-Week Range | $67.99 to $109.22 |
| RSI (14 Days) | 44.0 |
| Average Volume (20 Days) | 11.68M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 0.85x current liabilities, and total debt is 0.91x shareholder equity.
| Current Ratio | 0.85x |
|---|---|
| Quick Ratio | 0.66x |
| Debt / Equity | 0.91x |
| Debt / EBITDA | 3.72x |
| Debt / FCF | 4.71x |
| Interest Coverage | 4.95x |
Returns and Efficiency
Return on invested capital is 8.99% over the last 12 months, against a 5-year average of 5.44%.
| Return on Equity (ROE) | 13.72% |
|---|---|
| Return on Assets (ROA) | 4.28% |
| Return on Invested Capital (ROIC) | 8.99% |
| Return on Capital Employed (ROCE) | 9.20% |
| ROE (5Y Average) | 7.20% |
| ROA (5Y Average) | 2.23% |
| ROIC (5Y Average) | 5.44% |
| Asset Turnover | 1.64x |
| Inventory Turnover | 13.08x |
| Receivables Turnover | 10.21x |
| Cash Conversion Cycle | 36 days |
Taxes
Income tax took 8.85% of pretax income over the last 12 months.
| Income Tax (TTM) | $1.07B |
|---|---|
| Effective Tax Rate | 8.85% |
Scores
CVS has an Altman Z-Score of 2.49, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 2.49 |
|---|---|
| Altman Z Zone | Grey |
| Piotroski F-Score | 7 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $420.61B over the last 12 months is up 6.73% from the 12 months before.
| Revenue | $420.61B |
|---|---|
| Revenue Growth (YoY) | +6.73% |
| Gross Profit | $186.06B |
| Operating Income | $15.06B |
| Pretax Income | $12.12B |
| Net Income | $11.05B |
| EBITDA | $19.70B |
| EBIT | $15.18B |
| Reported EPS (TTM) | $8.33 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 31.19% of the $258.07B in total assets.
| Cash and Equivalents | $11.74B |
|---|---|
| Total Debt | $73.38B |
| Net Debt | $61.64B |
| Net Debt Per Share | $48.08 |
| Working Capital | -$13.71B |
| Shareholder Equity | $80.50B |
| Book Value Per Share | $62.79 |
| Tangible Book Value | -$29.20B |
| Total Assets | $258.07B |
| Total Liabilities | $177.39B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $3.14B of capital spending, operating cash flow left $15.57B of free cash flow.
| Operating Cash Flow | $18.71B |
|---|---|
| Capital Expenditures | $3.14B |
| Free Cash Flow | $15.57B |
| FCF Per Share | $12.17 |
| Depreciation and Amortization | $4.52B |
| Dividends Paid | $3.42B |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 3.58%, against a 5-year average of 2.86%.
| Gross Margin | 44.24% |
|---|---|
| Operating Margin | 3.58% |
| Pretax Margin | 2.88% |
| Net Margin | 2.63% |
| EBITDA Margin | 4.68% |
| EBIT Margin | 3.61% |
| FCF Margin | 3.70% |
| Gross Margin (5Y Average) | 37.15% |
| Operating Margin (5Y Average) | 2.86% |
| Net Margin (5Y Average) | 1.62% |
Growth
Revenue grew 7.63% a year over 3 years, and EPS fell 8.32% a year.
| Revenue Growth (3Y CAGR) | +7.63% |
|---|---|
| Revenue Growth (5Y CAGR) | +8.39% |
| EPS Growth (3Y CAGR) | -8.32% |
| EPS Growth (5Y CAGR) | -2.11% |
| FCF Growth (3Y CAGR) | -16.58% |
| FCF Growth (5Y CAGR) | -10.28% |
| Operating Income Growth (3Y CAGR) | -16.32% |
| Book Value Per Share Growth (2Y CAGR) | -0.20% |
Dividends and Yields
CVS pays out 18.23% of earnings as dividends.
| Dividend Per Share (Annual) | $2.66 |
|---|---|
| Dividend Yield | 3.10% |
| Payment Schedule | Quarterly |
| Dividend Growth (3Y CAGR) | +6.53% |
| Dividend Growth (5Y CAGR) | +5.87% |
| Payout Ratio | 18.23% |
| FCF Payout Ratio | 21.99% |
| Earnings Yield | 9.71% |
| FCF Yield | 14.15% |
| Shareholder Yield | 3.11% |
Stock Splits
The last split was a 2-for-1 forward split on Jun 7, 2005.
| Last Split Date | Jun 7, 2005 |
|---|---|
| Split Type | Forward split |
| Split Ratio | 2:1 |
Peer Position
Against 12 similar companies, CVS has the 11th highest P/E and the 11th highest P/S.
P/E RatioPeer median 17.9x
P/S RatioPeer median 0.5x
ROICPeer median 13.95%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +8.95%
Dividend YieldPeer median 0.68%
| P/E Ratio | 10.3x vs 17.9x median |
|---|---|
| P/S Ratio | 0.3x vs 0.5x median |
| ROIC | 8.99% vs 13.95% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +6.73% vs +8.95% median |
| Dividend Yield | 3.10% vs 0.68% median |
Analyst Forecast
Consensus estimates put revenue growth at 3.52% and EPS growth at 13.42% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +3.52% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +13.42% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About CVS
What is CVS's market cap?
CVS Health has a market cap of $113.35B. Its enterprise value, which adds debt and subtracts cash, is $174.99B.
What is CVS's P/E ratio?
CVS Health has a trailing P/E ratio of 10.3x and a forward P/E of 10.4x.
How many shares of CVS are outstanding?
CVS Health has 1.28B shares outstanding. The count is up 1.02% from a year earlier.
Does CVS pay a dividend?
Yes. CVS Health pays $2.66 a share a year, a dividend yield of 3.10%.
How much debt does CVS have?
CVS Health has $73.38B of total debt and $11.74B of cash and equivalents, a net debt position of $61.64B.
CVS pages: Overview, Dividends, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts